Esperion Therapeutics | ESPR - Loan Capital


Esperion Therapeutics reported $262.48M in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Alterity Therapeutics Limited AUD 103.21K 73.88K Jun/2023
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Cipla INR 2.98B 454.6M Sep/2025
CSL USD 10.69B 1.37B Jun/2025
Cytokinetics USD 158.75M 554.3M Sep/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 40.87B 6.69B Sep/2025
Esperion Therapeutics USD 262.48M 235.95M Jun/2024
Geron USD 119.26M 273K Sep/2025
Grifols EUR 10.67B 564.4M Sep/2025
Halozyme Therapeutics USD 800.07M 709.03M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
Merck USD 39.97B 6B Sep/2025
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 26M 6M Sep/2025
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 1.84B 298.68M Sep/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024